Elsevier Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Landau
    Landau
  3. Chung
    Chung
  4. Shah
    Shah
  5. Hassoun
    Hassoun
  6. Lesokhin
    Lesokhin
  7. Devlin
    Devlin
  8. Korde
    Korde
  9. Mailankody
    Mailankody
  10. Scordo
    Scordo

Groups

  1. Bone Marrow Transplant (39)
  2. Center for Hematologic Malignancies (39)
  3. Department of Medicine (39)
  4. Epidemiology and Biostatistics (39)
  5. Hematologic Malignancies, Division of (39)
  6. Survivorship Research (39)
  7. Biostatistics Service (38)
  8. Hematologic Malignancies Research (31)
  9. Myeloma (30)
  10. CTCR Scholars (25)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "David Chung"
  3. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (7)
Groups
  1. Bone Marrow Transplant (39)
  2. Center for Hematologic Malignancies (39)
  3. Department of Medicine (39)
  4. Epidemiology and Biostatistics (39)
  5. Hematologic Malignancies, Division of (39)
  6. Survivorship Research (39)

More Groups

People
  1. David Chung (39)
  2. Heather Landau (38)
  3. Sergio Giralt (38)
  4. Gunjan Shah (32)
  5. Alexander Lesokhin (29)
  6. Hani Hassoun (29)

More People

Years
  1. 2024 (1)
  2. 2023 (10)
  3. 2022 (7)
  4. 2021 (1)
  5. 2020 (3)
  6. 2019 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (21)
  2. Biology of Blood and Marrow Transplantation (15)
  3. Transplantation and Cellular Therapy (2)
  4. eClinicalMedicine (1)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save